APC-200

APC-200 is a first-in-class, orally administered small molecule drug that acts as a polyamine uptake inhibitor. It was initially developed by the University of Wisconsin and later advanced by Adamis Pharmaceuticals. The primary therapeutic focus for APC-200 has been prostate cancer, specifically both castrate-sensitive and castrate-resistant forms. Its mechanism involves inhibiting the cellular uptake of polyamines, which are organic cations essential for cell growth and proliferation—processes often upregulated in cancer cells. By blocking this pathway, APC-200 aims to suppress tumor progression in prostate cancer[1][2][7].